HRP20221194T1 - Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom - Google Patents
Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom Download PDFInfo
- Publication number
- HRP20221194T1 HRP20221194T1 HRP20221194TT HRP20221194T HRP20221194T1 HR P20221194 T1 HRP20221194 T1 HR P20221194T1 HR P20221194T T HRP20221194T T HR P20221194TT HR P20221194 T HRP20221194 T HR P20221194T HR P20221194 T1 HRP20221194 T1 HR P20221194T1
- Authority
- HR
- Croatia
- Prior art keywords
- pro
- preparation
- active compound
- pharmaceutically acceptable
- octg
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title claims 9
- 239000002552 dosage form Substances 0.000 title 1
- 230000002849 elastaseinhibitory effect Effects 0.000 title 1
- 239000000816 peptidomimetic Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 238000002360 preparation method Methods 0.000 claims 13
- 239000007788 liquid Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 239000006199 nebulizer Substances 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 239000007791 liquid phase Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000002500 ions Chemical class 0.000 claims 3
- 230000002685 pulmonary effect Effects 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000003125 aqueous solvent Substances 0.000 claims 2
- 238000009826 distribution Methods 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008249 pharmaceutical aerosol Substances 0.000 claims 2
- JINGUCXQUOKWKH-VIFPVBQESA-N (2s)-2-aminodecanoic acid Chemical compound CCCCCCCC[C@H](N)C(O)=O JINGUCXQUOKWKH-VIFPVBQESA-N 0.000 claims 1
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims 1
- 229930182820 D-proline Natural products 0.000 claims 1
- 125000000180 D-prolyl group Chemical group N1[C@@H](C(=O)*)CCC1 0.000 claims 1
- -1 acetate compound Chemical class 0.000 claims 1
- 239000007792 gaseous phase Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (17)
1. Farmaceutski Aerosol za plućnu primjenu koji sadrži dispergiranu tekuću fazu i kontinuiranu plinovitu fazu, naznačen time, što dispergirana tekuća faza
(a) sadrži vodene kapljice koje sadrže aktivni spoj
ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-);
ili bilo koju njegovu farmaceutski prihvatljivu sol; gdje
OctG je (S)-2-aminodekanska kiselina;
DPro je D-prolin;
(b) ima srednji promjer mase od 1,5 μm do 5 μm; i
(c) ima raspodjelu veličine kapljica sa standardnom geometrijskom devijacijom od 1,2 do 1,7, kako je izmjereno kako je opisano u specifikaciji.
2. Aerosol sukladno patentnom zahtjevu 1, naznačen time što je suprotni ion suprotan aktivnom spoju acetat.
3. Aerosol sukladno patentnom zahtjevu 1 ili 2 koji se ispušta iz generatora aerosola brzinom od najmanje 0,1 mL dispergirane tekuće faze po minuti.
4. Aerosol sukladno patentnom zahtjevu 1 ili 2 koji se ispušta iz generatora aerosola pri srednjoj brzini isporuke od najmanje 0,8 mg aktivnog spoja ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koje njegove farmaceutski prihvatljive soli; po minuti.
5. Tečni farmaceutski Pripravak za pripremu aerosola sukladno bilo kojem od patentnih zahtjeva 1 do 4 koji sadrži aktivni spoj ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koju njegovu farmaceutski prihvatljivu sol; u koncentraciji unutar raspona od 4 mg/mL do 100 mg/mL.
6. Pripravak sukladno patentnom zahtjevu 5 koji ima dinamičku viskoznost u rasponu od 0,8 mPas do 1,7 mPas.
7. Pripravak sukladno patentnom zahtjevu 5 ili 6 koji ima površinski tlak u opsegu od 25 mN/m do 80 mN/m.
8. Pripravak sukladno bilo kojem od patentnih zahtjeva 5 do 7 koji sadrži najmanje jedan ekscipijent za modificiranog ukusa.
9. Kruti farmaceutski pripravak za pripremu tekućeg pripravaka sukladno bilo kojem od patentnih zahtjeva 5 do 8, naznačen time, da pripravak sadrži aktivni spoj ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koju njegovu farmaceutski prihvatljivu sol; i gdje je kruti pripravak topiv ili dispergiran tekućem u vodenom otapalu, i gdje tekući pripravak sadrži koncentraciju aktivnog spoja unutar opsega od 4 mg/mL do 100 mg/mL; ili bilo koju njegovu farmaceutski prihvatljivu sol; gdje kruti farmaceutski pripravak dodatno sadrži natrijev klorid.
10. Pripravak sukladno patentnom zahtjevu 9, naznačen time što je suprotni ion suprotan spoju acetata.
11. Komplet za pripremu i isporuku farmaceutskog aerosola za plućnu primjenu sukladno patentnom zahtjevu 1, naznačen time, da komplet sadrži nebulizator i tekući pripravak sukladno patentnom zahtjevu 5; ili sadrži nebulizator i kruti farmaceutski pripravak sukladno patentnom zahtjevu 9.
12. Komplet sukladno patentnom zahtjevu 11, naznačen time što je suprotni ion aktivnog spoja acetat.
13. Komplet sukladno patentnom zahtjevu 11 ili 12, naznačen time, da je nebulizator odabran između skupine sastavljene od mlaznih nebulizatora, ultrazvučnih nebulizatora, piezoeLijektroničkih nebulizatora, nebulizatora mlaznih sudara, eLijektrohidrodinamičnih nebulizatora, nebulizatora s kapilarnom silom, perforiranih membranskih nebulizatora i nebulizatora s perforiranom vibrirajućom membranom.
14. Komplet sukladno bilo kojem od patentnih zahtjeva 11 do 13, naznačen time, da je raspršivač prilagođen da može raspršiti tekući pripravak brzinom od najmanje 0,8 mg aktivnog spoja ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koju njegovu farmaceutski prihvatljivu sol; po minuti.
15. Komplet sukladno bilo kojem od patentnih zahtjeva 11 do 14, naznačen time što je najmanje 70 tež. % od inkorporirane doze aktivnog spoja ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koje njegove farmaceutski prihvatljive soli sastavljeno od kapljica koje imaju srednji promjer mase ne veći od 5 μm; tako izmjeren kako je opisano u opisu.
16. Postupak pripreme perosola primjeren za plućnu primjenu, navedeni postupak uključuje korake
(a) osiguranja tekućeg farmaceutskog pripravaka koji sadrži aktivni spoj ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koju njegovu farmaceutski prihvatljivu sol; u koncentraciji unutar raspona od 4 mg/mL do 100 mg/mL;
(b) osiguranja nebulizatora podobnog za aerosolizaciju navedenog tekućeg farmaceutskog pripravaka pri srednjoj brzini isporuke od najmanje 0,8 mg aktivnog spoja ciklo(-OctG-Glu-Thr-Ala-Ser-lle-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili bilo koje njegove farmaceutski prihvatljive soli; po minuti; nebulizatora koji je nadalje prilagođen emitirati aerosol koji sadrži dispergiranu tekuću fazu koja ima srednji promjer mase od 1,5 μm do 5 μm; i koja ima raspodjelu veličine kapljica koja ima geometrijsku standardnu devijaciju od 1,2 do 1,7, tako izmjerenu kao što je opisano u opisu; i
(c) rukovanja nebulizatora da raspršuje tekući farmaceutski pripravak.
17. Postupak sukladno patentnom zahtjevu 16, naznačena time, da je tekući farmaceutski pripravak pripremljen pomoću slijedećih koraka:
(a1) osiguranja krutog farmaceutskog pripravaka koji sadrži aktivni spoj ciklo(-OctG-Glu-Thr-Ala-Ser-Ile-Pro-Pro-Gln-Lys-Tyr-DPro-Pro-); ili njegovu farmaceutski prihvatljivu sol;
(a2) otapanja ili dispergiranja navedenog krutog pripravka u tekućem Vodenom otapalu, na taj način pripremajući tekući farmaceutski pripravak u kojem je aktivni spoj ili njegova farmaceutski prihvatljiva sol prisutno/a u koncentraciji unutar opsega od 4 mg/mL do 100 mg/mL
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16020210 | 2016-05-31 | ||
| EP17733737.5A EP3463280B1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
| PCT/EP2017/025156 WO2017207117A1 (en) | 2016-05-31 | 2017-05-31 | Beta-hairpin peptidomimetic with elastase inhibitory activity and aerosol dosage forms thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221194T1 true HRP20221194T1 (hr) | 2022-12-09 |
Family
ID=56108445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221185TT HRP20221185T1 (hr) | 2016-05-31 | 2017-05-31 | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom |
| HRP20221194TT HRP20221194T1 (hr) | 2016-05-31 | 2017-05-31 | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221185TT HRP20221185T1 (hr) | 2016-05-31 | 2017-05-31 | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11235024B2 (hr) |
| EP (2) | EP3463281B1 (hr) |
| JP (4) | JP7286319B6 (hr) |
| KR (2) | KR102511284B1 (hr) |
| CN (3) | CN109310613A (hr) |
| AU (2) | AU2017273507B2 (hr) |
| BR (2) | BR112018074532B1 (hr) |
| CA (2) | CA3024521C (hr) |
| CL (2) | CL2018003391A1 (hr) |
| DK (2) | DK3463280T3 (hr) |
| EA (2) | EA201892819A1 (hr) |
| ES (2) | ES2927948T3 (hr) |
| HR (2) | HRP20221185T1 (hr) |
| HU (2) | HUE060393T2 (hr) |
| IL (2) | IL263112B2 (hr) |
| LT (2) | LT3463280T (hr) |
| MA (2) | MA45168A (hr) |
| MX (2) | MX2018014752A (hr) |
| PH (2) | PH12018502521A1 (hr) |
| PL (2) | PL3463280T3 (hr) |
| PT (2) | PT3463281T (hr) |
| RS (2) | RS63622B1 (hr) |
| SG (3) | SG11201810137UA (hr) |
| UA (2) | UA125900C2 (hr) |
| WO (2) | WO2017207118A1 (hr) |
| ZA (2) | ZA201807772B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3463280T (lt) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta plaukų segtuko struktūros peptido mimetikas, pasižymintis elastazės slopiklio aktyvumu ir jo aerozolinės vaisto formos |
| WO2021041264A1 (en) * | 2019-08-23 | 2021-03-04 | Ph Pharma Co., Ltd. | Use of a neutrophil elastase inhibitor in lung disease |
| CA3168807A1 (en) * | 2020-01-30 | 2021-08-05 | Vertex Pharmaceuticals Incorporated | Methods of treatment for alpha-1 antitrypsin deficiency |
| IL303021A (en) * | 2020-11-23 | 2023-07-01 | Spexis Ag | Peptidomimetic beta-herpain compositions and spray dosage forms thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE229812T1 (de) * | 1996-11-01 | 2003-01-15 | Xoma Technology Ltd | Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose |
| AU2006206272A1 (en) | 2005-01-21 | 2006-07-27 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion |
| WO2006087001A1 (en) * | 2005-02-17 | 2006-08-24 | Polyphor Ltd. | Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity |
| EP1712220A1 (en) * | 2005-04-15 | 2006-10-18 | PARI GmbH Spezialisten für effektive Inhalation | Pharmaceutical aerosol composition |
| BRPI0707634A2 (pt) * | 2006-02-09 | 2011-05-10 | Kamada Ltd | alfa-1 antitripsina para tratar episàdios de exacerbaÇço de doenÇas pulmonares |
| LT1991201T (lt) * | 2006-02-10 | 2018-07-25 | Pari Pharma Gmbh | Puškiami antibiotikai inhaliaciniam gydymui |
| WO2008025560A1 (en) * | 2006-09-01 | 2008-03-06 | Pari Pharma Gmbh | Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy |
| EP1927373B1 (en) * | 2006-11-30 | 2012-08-22 | PARI Pharma GmbH | Inhalation nebulizer |
| PL2567691T3 (pl) * | 2011-09-12 | 2015-05-29 | Meiji Seika Pharma Co Ltd | Kompozycje wodne obejmujące arbekacynę |
| WO2015096672A1 (zh) | 2013-12-23 | 2015-07-02 | 石家庄铁道大学 | 测试装置 |
| WO2015098872A1 (ja) | 2013-12-26 | 2015-07-02 | 株式会社カネカ | 太陽電池のｉ‐ｖ測定方法、太陽電池のｉ‐ｖ測定装置、太陽電池の製造方法、太陽電池モジュールの製造方法、および太陽電池モジュール |
| WO2015096873A1 (en) * | 2013-12-27 | 2015-07-02 | Polyphor Ag | Beta-hairpin peptidomimetics as selective elastase inhibitors |
| MX2016008468A (es) * | 2013-12-27 | 2016-09-26 | Polyphor Ag | Peptidomimeticos de horquilla beta como inhibidores de elastasa selectivos. |
| LT3463280T (lt) * | 2016-05-31 | 2022-09-26 | Spexis Ag | Beta plaukų segtuko struktūros peptido mimetikas, pasižymintis elastazės slopiklio aktyvumu ir jo aerozolinės vaisto formos |
-
2017
- 2017-05-31 LT LTEPPCT/EP2017/025156T patent/LT3463280T/lt unknown
- 2017-05-31 WO PCT/EP2017/025157 patent/WO2017207118A1/en unknown
- 2017-05-31 SG SG11201810137UA patent/SG11201810137UA/en unknown
- 2017-05-31 SG SG10202113280XA patent/SG10202113280XA/en unknown
- 2017-05-31 AU AU2017273507A patent/AU2017273507B2/en active Active
- 2017-05-31 WO PCT/EP2017/025156 patent/WO2017207117A1/en unknown
- 2017-05-31 ES ES17733737T patent/ES2927948T3/es active Active
- 2017-05-31 PT PT177337383T patent/PT3463281T/pt unknown
- 2017-05-31 UA UAA201812930A patent/UA125900C2/uk unknown
- 2017-05-31 MA MA045168A patent/MA45168A/fr unknown
- 2017-05-31 BR BR112018074532-4A patent/BR112018074532B1/pt active IP Right Grant
- 2017-05-31 CA CA3024521A patent/CA3024521C/en active Active
- 2017-05-31 US US16/305,714 patent/US11235024B2/en active Active
- 2017-05-31 DK DK17733737.5T patent/DK3463280T3/da active
- 2017-05-31 PL PL17733737.5T patent/PL3463280T3/pl unknown
- 2017-05-31 HU HUE17733738A patent/HUE060393T2/hu unknown
- 2017-05-31 JP JP2018562561A patent/JP7286319B6/ja active Active
- 2017-05-31 EP EP17733738.3A patent/EP3463281B1/en active Active
- 2017-05-31 MX MX2018014752A patent/MX2018014752A/es unknown
- 2017-05-31 LT LTEPPCT/EP2017/025157T patent/LT3463281T/lt unknown
- 2017-05-31 KR KR1020187036055A patent/KR102511284B1/ko active IP Right Grant
- 2017-05-31 RS RS20220923A patent/RS63622B1/sr unknown
- 2017-05-31 IL IL263112A patent/IL263112B2/en unknown
- 2017-05-31 HR HRP20221185TT patent/HRP20221185T1/hr unknown
- 2017-05-31 AU AU2017273508A patent/AU2017273508B2/en active Active
- 2017-05-31 IL IL263114A patent/IL263114B2/en unknown
- 2017-05-31 EA EA201892819A patent/EA201892819A1/ru unknown
- 2017-05-31 EP EP17733737.5A patent/EP3463280B1/en active Active
- 2017-05-31 RS RS20220922A patent/RS63639B1/sr unknown
- 2017-05-31 KR KR1020187036054A patent/KR102480800B1/ko active IP Right Grant
- 2017-05-31 US US16/305,518 patent/US11235023B2/en active Active
- 2017-05-31 DK DK17733738.3T patent/DK3463281T3/da active
- 2017-05-31 CA CA3024522A patent/CA3024522C/en active Active
- 2017-05-31 MX MX2018014425A patent/MX2018014425A/es unknown
- 2017-05-31 BR BR112018074551-0A patent/BR112018074551B1/pt active IP Right Grant
- 2017-05-31 CN CN201780033188.1A patent/CN109310613A/zh active Pending
- 2017-05-31 PL PL17733738.3T patent/PL3463281T3/pl unknown
- 2017-05-31 MA MA045167A patent/MA45167A/fr unknown
- 2017-05-31 HR HRP20221194TT patent/HRP20221194T1/hr unknown
- 2017-05-31 SG SG11201810138XA patent/SG11201810138XA/en unknown
- 2017-05-31 PT PT177337375T patent/PT3463280T/pt unknown
- 2017-05-31 JP JP2018562549A patent/JP2019523222A/ja active Pending
- 2017-05-31 EA EA201892818A patent/EA039603B1/ru unknown
- 2017-05-31 ES ES17733738T patent/ES2928050T3/es active Active
- 2017-05-31 CN CN201780033187.7A patent/CN109195580A/zh active Pending
- 2017-05-31 CN CN202211636345.7A patent/CN116159024A/zh active Pending
- 2017-05-31 HU HUE17733737A patent/HUE060119T2/hu unknown
- 2017-05-31 UA UAA201812929A patent/UA125899C2/uk unknown
-
2018
- 2018-11-19 ZA ZA2018/07772A patent/ZA201807772B/en unknown
- 2018-11-19 ZA ZA2018/07773A patent/ZA201807773B/en unknown
- 2018-11-28 CL CL2018003391A patent/CL2018003391A1/es unknown
- 2018-11-28 CL CL2018003390A patent/CL2018003390A1/es unknown
- 2018-11-29 PH PH12018502521A patent/PH12018502521A1/en unknown
- 2018-11-29 PH PH12018502522A patent/PH12018502522A1/en unknown
-
2021
- 2021-10-06 US US17/495,137 patent/US11844823B2/en active Active
-
2022
- 2022-01-04 JP JP2022000083A patent/JP2022078013A/ja active Pending
- 2022-10-20 JP JP2022168582A patent/JP2023017793A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221194T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| JP2018199688A5 (hr) | ||
| RU2548755C2 (ru) | Бесконсервантные составы, содержащие инсулин, и системы и способы для перевода в аэрозольное состояние | |
| JP2017502064A5 (hr) | ||
| RU2008136460A (ru) | Фармацевтический аэрозоль | |
| JP2016527275A5 (hr) | ||
| RU2014133362A (ru) | Системы и способы доставки сухих порошковых лекарств | |
| JP2014503598A5 (hr) | ||
| JP2014509313A5 (hr) | ||
| JP2015523395A5 (hr) | ||
| CA2516733A1 (en) | Process for the production of particles | |
| JP2013544781A5 (hr) | ||
| HRP20120812T1 (hr) | Upotreba soli acetilsalicilne kiseline u lijeäśenju virusnih infekcija | |
| JP2013534227A5 (hr) | ||
| JP2015505541A5 (hr) | ||
| HRP20231621T1 (hr) | Formulacije ciklosporina za upotrebu u prevenciji ili liječenju plućnog kroničnog odbacivanja transplantanta | |
| JP2007254421A (ja) | 吐出用液体、吐出方法、吐出用カートリッジ、吐出装置及び吐出用液体の液滴化方法 | |
| WO2023200459A1 (en) | Nasal spray bottle with improved nozzle and system of application | |
| KR20220158030A (ko) | 급성 폐손상 치료용 5-아미노-2,3-디히드로-1,4-프탈라진디온 | |
| JP2006087815A5 (hr) | ||
| KR20230027150A (ko) | 코로나바이러스 감염 치료용 화합물 | |
| MX2021006585A (es) | Ciclosporina a en forma solubilizada en liposomas (l-csa) para usarse en el tratamiento de enfermedades pulmonares mediante la inhalación de un aerosol generado por un nebulizador. | |
| Ochowiak et al. | The thermostated medical jet nebulizer: aerosol characteristics | |
| US20150031543A1 (en) | Compositions for aerosolization of highly conductive solutions | |
| PT108885B (pt) | Método de produção de partículas compósitas inaláveis mediante a utilização de um atomizador de três fluidos |